Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAL F02
2022-502184-38-00Phase 2Authorised
- Sponsor
- Alentis Therapeutics
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and crescentic glomerulonephritis (RPGN) comparing lixudebart + standard of care with placebo + standard of care (2 arms). Primary endpoint: Safety and tolerability of ALE.F02. Planned start Sep 2023; status: authorised.
02
Drugs
lixudebart
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)crescentic glomerulonephritis (RPGN)
Beyond the preview
Go deeper on 2022-502184-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502184-38-00.